uploads/2018/06/Vision-Care-1.png

JNJ’s Vision Care Segment Witnessed Solid Growth in Q1 2018

By

Updated

Vision Care segment’s revenue trends

Johnson & Johnson’s Vision Care segment generated revenues of $1.1 billion in the first quarter compared to $798.0 million in the first quarter of 2017, reflecting ~39.7% YoY (year-over-year) growth.

In the US and international markets, Johnson & Johnson’s Vision Care segment generated first-quarter revenues of $440.0 million and $675.0 million, respectively. This compared to $305.0 million and $493.0 million in the first quarter of 2017, respectively, reflecting ~44.3% and ~36.9% YoY growth.

Article continues below advertisement

Contact Lenses segment’s revenue trends

In the first quarter, Johnson & Johnson’s Contact Lenses unit generated revenues of $807.0 million compared to $683.0 million in the first quarter of 2017, reflecting ~18.2% YoY growth.

In the US market, Johnson & Johnson’s Contact Lenses segment’s revenues grew 20.7% to reach $309.0 million in the first quarter from $256.0 million in the first quarter of 2017. In the international markets, this segment generated revenues of $498.0 million in the first quarter, reflecting ~16.6% YoY growth

Surgical Vision Care segment

Johnson & Johnson’s Surgical Vision Care segment reported revenues of $308.0 million in the first quarter, compared to $115.0 million in the first quarter of 2017.

In the US and international markets, JNJ’s Surgical Vision Care segment generated first-quarter revenues of $131.0 million and $177.0 million, respectively, compared to $49.0 million and $66.0 million in the first quarter of 2017.

Recent developments

In June, the FDA approved Johnson & Johnson’s iDESIGN Refractive Studio, which can be utilized for customized LASIK treatment. Presently, iDESIGN is the only device that uses topography-integrated wavefront-guided technology. This technology allows doctors to undertake precise measurements of the eye inside and out for implementation of the LASIK procedure.

iDESIGN is approved for myopia, hyperopia, and mixed astigmatism. Studies estimate that ~130.0 million individuals could benefit from this procedure.

Among Johnson & Johnson’s (JNJ) peers in the vision care market, Cooper Vision (COO) reported revenues of $631.0 million in the second quarter. Johnson & Johnson’s peer in contact lenses market, Alcon, which is a subsidiary of Novartis (NVS), reported revenues of $1.8 billion in the first quarter.

Advertisement

More From Market Realist